- Home
- CALC vs LTRN Comparison
CALC vs LTRN Comparison
Compare CALC & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CALC
- LTRN
- Stock Information
- Founded
- CALC 2011
- LTRN 2013
- Country
- CALC United States
- LTRN United States
- Employees
- CALC N/A
- LTRN N/A
- Industry
- CALC Biotechnology: Pharmaceutical Preparations
- LTRN Biotechnology: Pharmaceutical Preparations
- Sector
- CALC Health Care
- LTRN Health Care
- Exchange
- CALC Nasdaq
- LTRN Nasdaq
- Market Cap
- CALC 22.9M
- LTRN 36.0M
- IPO Year
- CALC N/A
- LTRN 2020
- Fundamental
- Price
- CALC $1.64
- LTRN $3.66
- Analyst Decision
- CALC Strong Buy
- LTRN Strong Buy
- Analyst Count
- CALC 3
- LTRN 1
- Target Price
- CALC $16.33
- LTRN $25.00
- AVG Volume (30 Days)
- CALC 28.9K
- LTRN 227.0K
- Earning Date
- CALC 08-11-2025
- LTRN 08-07-2025
- Dividend Yield
- CALC N/A
- LTRN N/A
- EPS Growth
- CALC N/A
- LTRN N/A
- EPS
- CALC N/A
- LTRN N/A
- Revenue
- CALC N/A
- LTRN N/A
- Revenue This Year
- CALC N/A
- LTRN N/A
- Revenue Next Year
- CALC N/A
- LTRN N/A
- P/E Ratio
- CALC N/A
- LTRN N/A
- Revenue Growth
- CALC N/A
- LTRN N/A
- 52 Week Low
- CALC $1.42
- LTRN $2.55
- 52 Week High
- CALC $5.97
- LTRN $6.12
- Technical
- Relative Strength Index (RSI)
- CALC 49.89
- LTRN 63.16
- Support Level
- CALC $1.59
- LTRN $3.15
- Resistance Level
- CALC $1.69
- LTRN $3.31
- Average True Range (ATR)
- CALC 0.15
- LTRN 0.17
- MACD
- CALC 0.01
- LTRN 0.06
- Stochastic Oscillator
- CALC 52.26
- LTRN 87.14
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.